Cmax is out of the range [Study As­sess­ment]

posted by Mikalai  – Belarus, 2018-08-01 12:05  – Posting: # 19121
Views: 1,828

Dear all,
We recently conducted a BE trial. It was a classical 2-period, 2-sequence study of a drug that consists of a combination of two active substances. Unfortunately, results one of analytes, a parent drug, fell sightly outside of the 80-125% range, below 80% for Cmax. CV was below 30% and post-hoc power was less than 80% for this analyte. Are there any ways we can defend bioequivalence without conducting another BE trail? All other analytes fell within 80-125%. Specifically, what should we put in the protocol or in a supporting letter to justify our lower border of CI around 79% for Cmax?

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,817 posts in 4,200 threads, 1,361 registered users;
online 8 (0 registered, 8 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 15:58 CEST

A big computer, a complex algorithm and a long time
does not equal science.    Robert Gentleman

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5